IP Library Granted Patent US 6,969,526
Granted Patent B2
US 6,969,526 · App. 10/024,858 · Granted Nov 29, 2005

Paroxetine controlled release compositions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,969,526
App. No.
10/024,858
Granted
Nov 29, 2005
Kind
B2
Abstract

A controlled release or delayed release formulation contains a selective serotonin reuptake inhibitor (SSRI) such as paroxtine.

Claims (2)

1. A composition, that reduces the incidence of nausea and vomiting associated with the administration of paroxetine, comprising paroxetine, or a pharmaceutically acceptable salt thereof, in a controlled and delayed release swallow pharmaceutical formulation that, upon administration, releases the paroxetine predominantly in the smell intestine.

2. A method of treating one or more disease states selected from; Alcoholism, Anxiety, Depression, Obsessive Compulsive Disorder, Panic Disorder, Chronic Pain, Obesity, Senile Dementia, Migraine, Bulimia, Anorexia, Social Phobia, Pre-Menstrual Syndrome (PMS), Adolescent Depression, Trichotillomania, Dysthymla and Substance Abuse, which comprises administering an effective amount of a controlled and delayed release formulation of claim 1 to an individual in need thereof.

Assignments (1)
CHANGE OF NAME Recorded Jan 9, 2013
From: SMITHKLINE BEECHAM P.L.C.
To: SMITHKLINE BEECHAM LIMITED
Reel/Frame 029593/0104 →